Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD
Current smoking status detrimentally influenced onset attack recovery in AQP4-NMOSD and MOGAD patients, including visual recovery in MOGAD. Non-smoking VRFs influenced clinical and visual outcomes in AQP4-NMOSD.
Authors
- David Berhanu (ORCID: https://orcid.org/0000-0003-1851-7182)
- Fiona Chan (ORCID: https://orcid.org/0000-0002-7380-7783)
- Sara Samadzadeh (ORCID: https://orcid.org/0000-0003-3593-1852)
- Nasrin Asgari (ORCID: https://orcid.org/0000-0001-8551-0947)
- Ruth Geraldes (ORCID: https://orcid.org/0000-0001-5829-808X)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Maria Isabel Leite (ORCID: https://orcid.org/0000-0003-4407-5066)
- Anna Francis
- Jacqueline A. Palace (ORCID: https://orcid.org/0000-0003-4779-6133)
Institutions
- The University of Sydney (AU)
- University of Lisbon (PT)
- University of Southern Denmark (DK)
- John Radcliffe Hospital (GB)
- Frimley Health NHS Foundation Trust (GB)
- Humboldt-Universität zu Berlin (DE)
- University of Oxford (GB)
- Slagelse Hospital (DK)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1177/13524585251325069
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.36
Funders
- Amgen
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Guthy-Jackson Charitable Foundation
- European Committee for Treatment and Research in Multiple Sclerosis
- Argenx
- Horizon Therapeutics
- University of Oxford
- Fondation Charcot
- Santa Casa da Misericórdia de Lisboa
- Chugai Pharmaceutical
- UCB Pharma